C
Contraline
A medical device company developing a long-lasting, non-hormonal, and reversible male contraceptive using advancements in hydrogel technology
About Contraline
Contraline, Inc. is pioneering the future of male contraception with its groundbreaking implant technology. The company is focused on developing a long-lasting, safe, and effective contraceptive solution for men, which aims to eliminate the anxiety and inconvenience associated with current methods. Contraline's primary product is an investigational device designed to provide men with a reversible contraceptive option, marking the first significant advancement in male contraception since the vasectomy. The company operates in the healthcare and medical device market, targeting men and couples seeking reliable and hassle-free contraception. Contraline's business model revolves around the research, development, and eventual commercialization of its innovative contraceptive implant. Revenue generation is expected to come from product sales once regulatory approvals are obtained and the device is brought to market. The company is currently in the clinical trial phase, working towards proving the efficacy and safety of its device.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Charlottesville, United States
- Employees
- 30
- Open positions
- 3
- Dealroom signal
- 90.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Mentech, Biotech and Pharma, DT and LS, science-based
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Contraline.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $93M | $370M | BVF Partners · GV · Invus · Lumira Ventures | ↗ |
| EARLY VCOther financing | Nov 2022 | $7.2M | $54M | Graphene Ventures · ShangBay Capital · MBX Capital · RHIA Ventures | ↗ |
Growth signals
Latest recorded traffic for Contraline is 21K monthly website visits, down 12.5% over the last three months. Contraline's team grew 25% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
Kima Ventures
Jaffray Woodriff
William B. Stilley
Founders Fund
Cyan Banister
Abstract Ventures
CIT GAP Funds
Jason Calacanis
Andy Sack
Afton Scientific
Series A14 investors entered at this stage
Bill Smith- SVStrawberry Creek Ventures
Alumni Ventures
MBX Capital
Graphene Ventures
ShangBay Capital
Smith Ventures
RHIA Ventures
MetaPlanet
BVF Partners
RA Capital Management
GV
Invus
Lumira Ventures
Other known investors1 additional known investor
University of Virginia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Contraline on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Contraline’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.